EGLN1抗体—艾普蒂

The EGLN1 antibody is a crucial tool in studying the EGLN1 protein, also known as Prolyl Hydroxylase Domain-containing protein 2 (PHD2), a central regulator of cellular oxygen sensing. EGLN1 belongs to the prolyl hydroxylase family and plays a pivotal role in the hypoxia-inducible factor (HIF) pathway. Under normoxic conditions, EGLN1 hydroxylates specific proline residues on HIF-α subunits, marking them for proteasomal degradation via the von Hippel-Lindau (VHL) complex. This process is suppressed during hypoxia, enabling HIF-α accumulation and activation of genes involved in angiogenesis, erythropoiesis, and metabolic adaptation. Dysregulation of EGLN1 is linked to cancers, cardiovascular diseases, and ischemic disorders. Antibodies targeting EGLN1 are widely used in research to detect its expression, localization, and activity in tissues or cell lines via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They also aid in studying EGLN1's interactions with HIF and other substrates, as well as its response to oxygen levels or pharmacological inhibitors. Understanding EGLN1's function through antibody-based assays provides insights into hypoxia-related pathologies and supports therapeutic development targeting the HIF pathway.